On 9th March 2010, the NICE Appraisal Committee met to discuss consultation comments on this appraisal topic. As part of its consultation response, the marketing authorisation holder for everolimus (Novartis) submitted further evidence and analyses. In line with NICE processes, further evidence or analyses can only be accepted if either the Committee has asked NICE to seek clarification from the manufacturer or sponsor of the technology on the key evidence submitted, or if the Centre or Programme Director has agreed to accept new evidence before it is submitted. Neither of these happened on this occasion. In acknowledging that Committee hadn’t requested further evidence, the Committee Chair considered that it would be appropriate to review the other consultation responses at its meeting of 9 March. Full consideration of the information by the Evidence Review Group was therefore not possible before the Committee meeting. The Committee also considered the potential relevance of the new information and agreed that it was important to consider it after review by the Evidence Review Group. The Committee will therefore continue consideration of this topic at its meeting on 12th May 2010.